Welcome to the e-CCO Library!

P577: Drug Induced Liver Injury (DILI) secondary to biologic therapy in IBD: ECCO- CONFER Series
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Lisle1, S. Myers1, D. Pugliese2, T. Raine3, A. C. de Vries4, K. Katsanos5, R. Filip6, K. Karmiris7, S. Sebastian*1,8

Created: Friday, 22 February 2019, 9:41 AM
P577: Mucosal eosinophil abundance in non-inflamed colonic tissue predict response to vedolizumab induction therapy in inflammatory bowel disease
Year: 2022
Source: ECCO'22
Authors: Gabriëls, R.Y.(1);Bourgonje, A.R.(1);von Martels, J.(1);Blokzijl, T.(1);Weersma, R.(1);Galinsky, K.(2);Julius, J.(2);Faber, K.N.(1);Kats-Ugurlu, G.(3);Dijkstra, G.(1);
Created: Friday, 11 February 2022, 3:56 PM
P577: Withdrawal of thiopurines in patients with Ulcerative Colitis in remission
Year: 2021
Source: ECCO'21 Virtual
Authors: Amor Costa, C.(1);Suárez Ferrer, C.(1);Poza Cordón, J.(1);Rueda García, J.L.(1);Sánchez Azofra, M.(1);Martín Arranz, E.(1);González Diaz, I.(1);Amiama Roig, C.(1);García Ramirez, L.(1);Martín Arranz, M.D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P578 Inter-observer agreement of an expert panel for gastrointestinal ultrasound in ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. de Voogd1, R. Wilkens2, K. Gecse1, M. Allocca3, K. Novak4, C. Lu4, G. D’Haens1, C. Maaser5, International Bowel UltraSound (IBUS) - Group

Created: Thursday, 30 January 2020, 10:12 AM
P578: Adriatic-Balkan regional survey on COVID-19 in Inflammatory Bowel Disease patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Borzan, V.(1,2);Orsic Fric, V.(1,2);Borzan, B.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P578: Evolution of Crohn's disease treatment in clinical practice: a 25 year single centre cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hartery K., Moran C., Sheridan J., Keegan D., Byrne K., Horgan G., Doherty G., Cullen G., Buckley M., Mulcahy H.

Created: Wednesday, 20 February 2019, 10:36 AM
P578: Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Panés, J.(1)*;Panaccione, R.(2);Sands, B.(3);Gasink, C.(4);Marano, C.(5);Ma, T.(4);Hoops, T.(6);
Created: Friday, 14 July 2023, 11:05 AM
P578: Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients – a multicentre study on efficacy and drug sustainability
Year: 2022
Source: ECCO'22
Authors: Lontai, L.(1);Gonczi, L.(1);Balogh, F.(1);Komlodi, N.(1);Resal, T.(2);Farkas, K.(2);Molnar, T.(2);Golovics, P.(3);Schafer, E.(3);Szamosi, T.(3);Miheller, P.(4);Ilias, A.(1);LakatosPhD, P.L.(1,5);
Created: Friday, 11 February 2022, 3:56 PM
P578: Therapeutic strategies in the approach of paradoxical psoriasis in IBD: experience of a centre
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Santos*1, V. Gamelas2, D. Carvalho2, C. Bernardes2, J. Saiote2, J. Ramos2

Created: Friday, 22 February 2019, 9:41 AM
P578: Therapy refractory ulcerative colitis patients may benefit from appendectomy: long-term clinical results from a multicentre prospective cohort series
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.E. Stellingwerf1*, S. Sahami1, D.C. Winter2, H.E. Mulcahy2, G. Doherty2, G. Cullen2, S. Martin2, G.R. D'Haens3, W.A. Bemelman1, C.J. Buskens1

Created: Thursday, 21 February 2019, 9:14 AM
P579 Randomised open-label controlled trial of ciprofloxacin/doxycycline/hydroxychloroquine combination compared with standard budesonide in active Crohn’s disease (APRICOT)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.M. Rhodes1, S. Subramanian2, P. Flanagan3, G. Horgan4, K. Martin2, J. Mansfield5, M. Parkes6, A. Hart7, H. Dallal8, T. Iqbal9, J. Butterworth10, K. Culshaw11, C. Probert1

Created: Thursday, 30 January 2020, 10:12 AM
P579: Complete disease resolution after allogenic hematopoietic stem cell transplantation in children with very early onset inflammatory disease and no identified monogenic mutation
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Zambrano Perez A.*1, Elawad M.2, Kiparissi F.1, Shah N.1, Chadokufa S.1, Sider S.1, Huggett B.1

Created: Wednesday, 20 February 2019, 10:36 AM
P579: Online Education Significantly Improved Gastroenterologists' Knowledge of Treatment Options and Therapeutic Goals in Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Bell, E.(1);Calle, M.(2);Vermeire, S.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P579: Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s disease
Year: 2022
Source: ECCO'22
Authors: Derikx, L.(1,2);Plevris, N.(2);Su, S.(2);Gros, B.(2);Lyons, M.(2);Siakavellas, S.(2);Constantine-Cook, N.(3,4);Jenkinson, P.(2);O'Hare, C.(2);Merchant, L.(2);Noble, C.(2);Arnott, I.(2);Jones, G.(2,5);Lees, C.(2,4);
Created: Friday, 11 February 2022, 3:56 PM
P579: Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Buisson, A.(1)*;Serrero, M.(2);Altwegg, R.(3);Guilmoteau, T.(1);Bouguen, G.(4);Nachury, M.(5);Amiot, A.(6);Vuitton, L.(7);Treton, X.(8);Caillo, L.(9);Pereira, B.(10);Fumery, M.(11);
Created: Friday, 14 July 2023, 11:05 AM
P579: Risk of CMV reactivation in UC patients with previous history of CMV infection following infliximab or vedolizumab treatments
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Hommel1*, X. Roblin2,3, L. Brichet2,3, B. Bihin4, S. Pillet3,5, J.-F. Rahier1

Created: Thursday, 21 February 2019, 9:14 AM
P579: Wearable Devices Can Predict Disease Activity in inflammatory bowel disease Patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. H. Sossenheimer*1, O. V. Yvellez1, M. Andersen Jr1, T. Pearl1, K. El Jurdi1, D. B. Rubin1, A. Mayampurath2, D. T. Rubin1

Created: Friday, 22 February 2019, 9:41 AM
P580 Irritable bowel syndrome in inflammatory bowel disease after remission: correlation with remission patterns and inflammation
Year: 2020
Source:

ECCO'20 Vienna

Authors:

O. Sezgin1, B. Boztepe2, E. Altintas1, D. Çelikcan3

Created: Thursday, 30 January 2020, 10:12 AM
P580: Benchmarking IBD Pharmacy Services to optimise, strengthen and align IBD Expert Pharmacy Practice
Year: 2021
Source: ECCO'21 Virtual
Authors: St Clair Jones, A.(1);Meade, U.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P580: Early intestinal ultrasound assessment predicts endoscopic response and remission on anti-TNF treatment in Crohn’s Disease – a prospective longitudinal cohort study
Year: 2022
Source: ECCO'22
Authors: de Voogd, F.(1);Bots, S.(1);Gecse, K.(1);Gilja, O.H.(2);D'Haens, G.(1);Nylund, K.(2);
Created: Friday, 11 February 2022, 3:56 PM